objectives to analyze the characteristics of end-stage multiple myeloma patients in order to introduce optimal therapeutic strategies for mm.
目的:分析多发性骨髓瘤(mm)终末期患者的临床特点,以指导临床采用最佳的治疗策略。
conclusion the high-dose dexamethasone-based regiments are safe and effective for newly diagnosed multiple myeloma patients with renal impairment.
结论基于大剂量地塞米松的化疗方案可以安全、有效地治疗合并肾功能不全的初治多发性骨髓瘤患者。
revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
revlimid和类固醇地塞米松联合用药被批準用于多发性脊髓瘤和罕见病骨髓增生异常综合征 的治疗。其2009年的销售额为17亿美元。
abstract:objective to evaluate the efficacy and safety of high-dose dexamethasone-based regiments in newly diagnosed multiple myeloma patients with renal impairment.
摘要:目的评估基于大剂量地塞米松的化疗方案治疗合并肾功能不全的初治多发性骨髓瘤患者的疗效和安全性。